Heart Protection Study 2 - Treatment of HDL to reduce the incidence of vascular events (HPS2-Thrive);

Abstract

review and commentary on the results of the HPS2 Thrive study with emphasis on their impact on current clinical practice.

Keywords

• Simvastatin
• nician
• laropiprant
• cardiovascular risk